Treatment Response Adapted Hybrid Radiotherapy in Metastatic Non-small Cell Lung Cancer Receiving First-line Immunotherapy

This study is a multicenter, randomized controlled clinical trial to explore the preliminary efficacy and safety of treatment response adapted hybrid radiotherapy (LDRT and SBRT) in the first-line treatment of immunotherapy combined with chemotherapy for advanced driver-gene negative NSCLC, and to provide new ideas for the comprehensive treatment of advanced NSCLC

Trial Details

NCT ID

NCT06313541

Phase

PHASE2

Sponsor

Fudan University

Status

RECRUITING

Cancer Type

Non-Small Cell (NSCLC) Lung Cancer

Interventions

SBRT or LDRT
PD-1/PD-L1 inhibitor combined with platinum-based chemotherapy

Locations (sample)

Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

ECOG functional status score was 0-1.
Histologically confirmed stage IV primary NSCLC;
Genetic testing showed that the common driver genes including EGFR, ALK and ROS-1 were negative;
Patients with brain metastases were eligible if they were neurologically asymptomatic and had stable disease without receiving systemic glucocortic…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →